一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes.
A combination treatment with a water extract from Euglena gracilis and anti-PD-1 antibody strongly inhibits growth of lung cancer in mice through stimulating tumor-infiltrating lymphocytes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在此,我们研究了口服纤细裸藻水提取物(EWE)导致的肺癌生长抑制与T细胞刺激之间的关系。研究发现,口服EWE主要增加TIL(肿瘤浸润淋巴细胞)(TILs)中PD-1和PD-L1的mRNA和蛋白质,这与小鼠肿瘤重量的显著降低相关。EWE与抗PD-1抗体联合治疗通过增加TILs数量并减轻T细胞耗竭,比单独使用任一治疗更显著地抑制了小鼠肺部肿瘤的生长。短链脂肪酸——此前已证明在口服EWE处理的小鼠肠道中增加——在细胞培养中增加了脾细胞中PD-1和PD-L1的表达,但未增加肺癌细胞中的表达。这些结果表明,EWE诱导的短链脂肪酸增加、TILs中PD-1表达的升高以及肺部肿瘤生长的抑制之间存在密切关系。此外,EWE增强了基于抗PD-1抗体的免疫检查点阻断疗法对非小细胞肺癌的疗效。
Here, we investigated the relationship between the attenuation of lung cancer growth due to oral administration of Euglena gracilis water extract (EWE) and T cell stimulation. Orally administered EWE was revealed to increase PD-1 and PD-L1 mRNA and proteins primarily in tumor-infiltrating lymphocytes (TILs), which was correlated with a significant decrease in the tumor weights in mice. A combination treatment with EWE and anti-PD-1 antibody significantly decreased the growth of murine lung tumors more than treatment with either alone by increasing the number of TILs and attenuating T cell exhaustion.
Short-chain fatty acids, which were previously shown to be increased in intestines of mice treated with oral EWE, increased both PD-1 and PD-L1 expression in splenocytes, but not in lung cancer cells in cell culture. These results suggest there is a close relationship between the EWE-induced increase of short-chain fatty acids, the increase of PD-1 expression in TILs, and the attenuation of lung tumor growth.
Furthermore, EWE enhances the efficacy of anti-PD-1 antibody-based immune checkpoint blockade therapy against non-small cell lung cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。